Heron Therapeutics Financial Statements (HRTX)
|
|
|
|
Report date
|
|
|
28.02.2022 |
29.03.2023 |
12.03.2024 |
27.02.2025 |
26.02.2026 |
|
11.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
86.3 |
107.7 |
127.0 |
144.3 |
154.9 |
|
150.7 |
|
Operating Income, bln rub |
|
|
-217.8 |
-174.7 |
-110.6 |
-11.5 |
-2.54 |
|
-10.5 |
|
EBITDA, bln rub |
? |
|
-215.3 |
-176.7 |
-103.8 |
-5.06 |
-17.9 |
|
-20.6 |
|
Net profit, bln rub |
? |
|
-220.7 |
-182.0 |
-110.6 |
-13.6 |
-20.2 |
|
-30.9 |
|
|
OCF, bln rub |
? |
|
-203.4 |
-146.9 |
-58.8 |
-22.5 |
-27.6 |
|
-20.3 |
|
CAPEX, bln rub |
? |
|
3.02 |
1.83 |
1.55 |
1.71 |
0.317 |
|
0.599 |
|
FCF, bln rub |
? |
|
-206.4 |
-148.7 |
-60.3 |
-24.2 |
-27.9 |
|
-20.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
258.2 |
227.5 |
172.6 |
117.2 |
116.1 |
|
117.6 |
|
Cost of production, bln rub |
|
|
46.0 |
54.9 |
65.1 |
38.6 |
41.3 |
|
43.5 |
|
R&D, bln rub |
|
|
130.8 |
82.7 |
39.1 |
16.7 |
12.4 |
|
12.5 |
|
Interest expenses, bln rub |
|
|
2.41 |
2.47 |
3.87 |
6.03 |
0.000 |
|
3.90 |
|
|
Assets, bln rub |
|
|
305.7 |
251.0 |
222.5 |
233.1 |
255.9 |
|
246.2 |
|
Net Assets, bln rub |
? |
|
77.6 |
13.6 |
-34.0 |
-33.7 |
14.3 |
|
9.14 |
|
Debt, bln rub |
|
|
159.5 |
157.5 |
179.6 |
177.8 |
140.6 |
|
141.6 |
|
Cash, bln rub |
|
|
157.6 |
84.9 |
80.4 |
59.3 |
46.6 |
|
44.8 |
|
Net debt, bln rub |
|
|
1.92 |
72.6 |
99.2 |
118.5 |
94.0 |
|
96.9 |
|
|
Ordinary share price, rub |
|
|
9.13 |
2.50 |
1.70 |
1.53 |
1.30 |
|
0.871 |
|
Number of ordinary shares, mln |
|
|
98.5 |
109.0 |
138.1 |
152.4 |
166.7 |
|
189.6 |
|
|
Market cap, bln rub |
|
|
899 |
272 |
235 |
233 |
217 |
|
165 |
|
EV, bln rub |
? |
|
901 |
345 |
334 |
352 |
311 |
|
262 |
|
Book value, bln rub |
|
|
78 |
14 |
-34 |
-34 |
14 |
|
9 |
|
|
EPS, rub |
? |
|
-2.24 |
-1.67 |
-0.80 |
-0.09 |
-0.12 |
|
-0.16 |
|
FCF/share, rub |
|
|
-2.10 |
-1.36 |
-0.44 |
-0.16 |
-0.17 |
|
-0.11 |
|
BV/share, rub |
|
|
0.79 |
0.12 |
-0.25 |
-0.22 |
0.09 |
|
0.05 |
|
|
EBITDA margin, % |
? |
|
-249.3% |
-164.1% |
-81.7% |
-3.50% |
-11.5% |
|
-13.6% |
|
Net margin, % |
? |
|
-255.6% |
-169.1% |
-87.0% |
-9.41% |
-13.0% |
|
-20.5% |
|
FCF yield, % |
? |
|
-23.0% |
-54.6% |
-25.7% |
-10.4% |
-12.9% |
|
-12.6% |
|
ROE, % |
? |
|
-284.5% |
-1 341% |
325.4% |
40.4% |
-140.9% |
|
-338.6% |
|
ROA, % |
? |
|
-72.2% |
-72.5% |
-49.7% |
-5.82% |
-7.89% |
|
-12.6% |
|
|
P/E |
? |
|
-4.07 |
-1.50 |
-2.12 |
-17.2 |
-10.7 |
|
-5.34 |
|
P/FCF |
|
|
-4.36 |
-1.83 |
-3.89 |
-9.62 |
-7.77 |
|
-7.92 |
|
P/S |
? |
|
10.4 |
2.53 |
1.85 |
1.62 |
1.40 |
|
1.10 |
|
P/BV |
? |
|
11.6 |
20.1 |
-6.91 |
-6.93 |
15.1 |
|
18.1 |
|
EV/EBITDA |
? |
|
-4.19 |
-1.95 |
-3.22 |
-69.6 |
-17.4 |
|
-12.7 |
|
Debt/EBITDA |
|
|
-0.01 |
-0.41 |
-0.96 |
-23.4 |
-5.26 |
|
-4.71 |
|
|
R&D/CAPEX, % |
|
|
4 329% |
4 532% |
2 533% |
977.9% |
3 921% |
|
2 093% |
|
|
CAPEX/Revenue, % |
|
|
3.50% |
1.69% |
1.22% |
1.18% |
0.20% |
|
0.40% |
|
| Heron Therapeutics shareholders |
